Though there are four histone deacetylase (HDAC) inhibitors that are FDA approved to treat some forms of lymphoma, there’s less evidence for their efficacy in solid tumors. Now, new findings in mice ...
Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the ...
Most pancreatic tumors are surrounded by a thick, nearly impenetrable wall of fibrosis— scar tissue—that makes it hard for drugs to access and destroy the cancer cells. Researchers at the Salk ...
Scientists from the Icahn School of Medicine at Mount Sinai (MSSM) have published a study that describes the biological mechanism used by a family of proteins called histone deacetylases to activate ...
As gene regulation changes in Alzheimer’s disease, scientists believe that histone deacetylases (HDACs) go into overdrive, shutting down transcription of certain genes. Consequently, several research ...
Abcam provides a full array of HDAC antibodies from all the four classes of deacetylase. Many vital cell programs such as regulation of transcription, progression of the cell cycle and other ...
Alkermes is bolstering its neuroscience pipeline by acquiring Rodin Therapeutics, a biotech firm developing treatments for diseases caused by synaptic dysfunction. Rodin investors will get $100 ...
SAN ANTONIO -- Adding a histone deacetylase (HDAC) inhibitor to standard endocrine therapy led to a modest but statistically significant improvement in progression-free survival (PFS) in advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback